Company analysis reveals success of its proprietary loading technology for production of exosome-based therapeutics
NurExone is providing an updated version of a previous release released yesterday to replace several sentences and numbers that contained errors.
CALGARY, Alberta–(Newsfile Corp.–December 1, 2022)–NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (the “Company” or “NurExone”), a trauma A biopharmaceutical company developing bioguided exosome therapy (“ExoTherapy”) for patients with spinal cord injury, today reported a pre-completion clinical loading efficiency study demonstrating that its innovative and proprietary loading technology has the potential to be a therapeutic An efficient process for the loading of sexual molecular cargo into exosomes. In exosome-based therapies, loaded exosomes are biologically directed to target inflamed tissues to “dock” and unload their therapeutic substances, thereby creating a healing environment.
The company’s exosome-based therapeutic production platform program includes: (i) large-scale exosome production, (ii) therapeutic cargo and (iii) unique technology for loading therapeutic cargo. Prior scientific research results and initiatives have demonstrated the efficiency of the company’s large-scale exosome production process and the effectiveness of the company’s proprietary small interfering RNA (“siRNA”) sequences as therapeutic cargo. This recent study analyzed the company’s technology for loading therapeutic cargo into exosomes.
The findings demonstrate that the loading portion of NurExone does not impair the function of the siRNA to inhibit gene expression, and that the proprietary technology achieves the desired loading efficiency. As highlighted in Figure 1, the function of siRNA conjugated to the payload moiety was assessed by measuring PTEN inhibition in cells.Inhibition of the protein PTEN promotes axonal regeneration and neural repair[1], a key element of neuronal regeneration after traumatic spinal cord injury. Figure 2 shows a visual inspection using the gold standard hydrophobic-loaded moiety as a positive control versus the NurExone-loaded technology, which uses a proprietary hydrophilic moiety attached to its molecular cargo. Figure 3 shows percent load equivalence, as measured by co-localization of exosomes and their therapeutic cargo, a standard metric that enables companies to have their own proprietary patented technology.
NurExone intends to monetize its proprietary technology platform and will explore potential licensing opportunities once this loading technology is finalized.
Dr Lior Shaltiel, CEO of NurExone, commented: “Achieving the promise of exosome-based therapeutics requires efficient techniques for loading therapeutic molecules into exosomal nanocarriers. We believe that our innovative and exclusive loading technology overcomes this industry barriers, which allows us to take advantage of potential technology platform licensing opportunities and the resulting commercialization of our ExoTherapy products.”
For the potential treatment of patients with traumatic spinal cord injury, NurExone intends to use its ExoTherapy’s proprietary exosomes as bioguided nanocarriers to deliver specialized siRNA therapeutic compounds to the targeted area. The delivered molecules promote an environment that induces the healing process at the target site.
Figure 1: Function
siRNA combined with NurExone’s proprietary loading moiety
To view an enhanced version of Figure 1, visit:
https://images.newsfilecorp.com/files/3274/146482_f1nex.jpg.
The figure above demonstrates that NurExone’s proprietary siRNA-conjugated payload moiety does not affect the efficiency of NUR001 siRNA knockdown of PTEN expression (RNA) after transfection of HEK293 cells.In terms of PTEN inhibition in HEK293 cells, there was no statistical difference between NUR001, NUR001 + Hydrophobic Loaded fraction as standard and NUR001 + NurExo-Load (proprietary loading technology)
Figure 2: Loading efficiency analysis (visual inspection)
Comparison of NurExone loading process and control process
To view an enhanced version of Figure 2, visit:
https://images.newsfilecorp.com/files/3274/146482_f2nex.jpg.
This study used EVs (exosomes) isolated from bone marrow-derived mesenchymal stem cells MSCs (violet) loaded with Cy3-labeled siRNA (green) for both processes. The siRNA-loaded exosomes were observed using a super-resolution microscope (Light Sheet, Zeiss Z7). Colocalization (white) analysis showed that the loading efficiency of the NurExone loading process was approximately 60%, similar to the results obtained for the control group.
Figure 3: Loading efficiency analysis (statistical analysis)——
Comparison of NurExone loading process and control process
To view an enhanced version of Figure 3, visit:
https://images.newsfilecorp.com/files/3274/146482_f3nex.jpg.
The graph above compares the percent loading of EVs loaded with siRNA-PTEN conjugated to a NurExone proprietary moiety compared to controls. NurExone’s technology achieved a loading efficiency of 62.3%, showing substantial equivalence to the control process (59.5%).
About NurExone Biologic Inc.
NurExone Biologics, a TSXV-listed pharmaceutical company, through its wholly-owned subsidiary Nurexone Biologic Ltd., has developed a platform for the non-invasive delivery of bioguided ExoTherapy to patients suffering traumatic spinal cord injuries. ExoTherapy has a proof of concept in animal studies at the Technion, Israel Institute of Technology. NurExone intends to translate the therapy into humans and the company holds an exclusive worldwide license from the Technion and Tel Aviv University for the development and commercialization of the technology.
For more information, visit www.nurexone.com or follow NurExone on LinkedIn, Twitter, Facebook or YouTube.
For more information, please contact:
Dr Lior Chatier
Chief Executive Officer and Director
Tel: +972-52-4803034
E-mail: info@nurexone.com
For investors:
Investor Relations
IR@nurexone.com
+1 905-347-5569
forward-looking statement
This press release contains certain forward-looking statements, including regarding the Company’s future plans and intellectual property, scientific and development activities to be undertaken by the Company, exosome payloads, potential future manufacturing, clinical and marketing activities and, under certain conditions, treat. Where possible, words such as “may”, “will”, “should”, “could”, “anticipate”, “plan”, “intend”, “anticipate”, “believe”, “estimate”, “forecast” or “potential” or the negative or other variations of these words, or similar words or phrases, have been used to identify these forward-looking statements. These statements reflect management’s current beliefs and are based on information currently available to management as of the date hereof. Forward-looking statements involve significant risks, uncertainties and assumptions. Many factors could cause actual results, performance or achievements to differ materially from those discussed or implied in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks associated with the Company’s early development stages, insufficient revenue to date, government regulation, market acceptance of its products, rapid technological change, reliance on key personnel, protection of the Company’s intellectual property and Reliance on the company’s strategic partners. These factors should be carefully considered, and readers should not place undue reliance on forward-looking statements. Although the forward-looking statements contained in this press release are based on what management believes are reasonable assumptions, the company cannot assure readers that actual results will be consistent with these forward-looking statements. These forward-looking statements are made as of the date of this press release, and the company undertakes no obligation to update or revise them to reflect new events or circumstances, except as required by law.
Neither TSX Venture Exchange nor its regulatory service provider (as that term is defined in the policies of TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
[1] Yosuke Ohtake, Umar Hayat, and Shuxin Li, MD, PhD, PTEN Inhibition and Axonal Regeneration and Neural Repair, Neural Regen Res. 2015 Sep;10(9):1363-1368, National Institutes of Health Library of Medicine.
To view the source version of this news release, please visit https://www.newsfilecorp.com/release/146482